Daily Bulletin

Men's Weekly

.

First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort 2 of the 64Cu/67Cu SARTATE™ neuroblastoma...

Read more: First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

Business News

Finding Reliable Equipment Hire for Your Construction Projects

Construction projects are a heavy reliance on getting the right equipment to the right place, at the right time. Whether you're breaking ground, moving earth, paving roads, or just building, heavy m...

Daily Bulletin - avatar Daily Bulletin

Townsville Woman’s Solution for Evacuations – Hit the Road

Angela lives in Townsville’s Railway Estate with her two beloved labradors. Railway Estate is just one Townsville area hit so regularly by flooding that residents have all but given up. After the 2019...

Daily Bulletin - avatar Daily Bulletin

Tuning Strategies for Modern Trucks: Putting SCT X4 Performance to the Test

The Case for Aftermarket Tuning in Modern Trucks Factory programmers aren't trying to thrill you. They’re chasing emissions compliance, warranty safety nets, and broad market compatibility. That co...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business